Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;254(3):293-300.
doi: 10.1007/s00232-020-00167-6. Epub 2021 Jan 20.

Current Trends in GPCR Allostery

Khuraijam Dhanachandra Singh  1 , Sadashiva S Karnik  2
Affiliations

Current Trends in GPCR Allostery

Khuraijam Dhanachandra Singh et al. J Membr Biol. 2021 Jun.

Abstract

GPCRs remain the most important drug target comprising ~ 34% of the Food and Drug Administration (FDA)-approved drugs. In modern pharmacology of GPCRs, modulating receptor signaling based on requirement of a specific disorder is of immense interest. Classical drugs targeting orthosteric sites in GPCRs completely block the binding of endogenous ligand and consequently inhibit all important signals from a GPCR. Some of many signals elicited by the endogenous ligands may play vital role and inhibiting these may also cause severe side effects in the long run. However, allosteric drugs can modulate GPCR signaling without blocking the endogenous ligand binding. Therefore, allosteric drugs can maintain beneficial signaling of the receptor and prevent unwanted side effects. In this chapter, we will discuss GPCR crystal structures solved with allosteric ligands, advantages of allosteric drugs, and allosteric drugs which are in clinical use or trials.

Keywords: Allosteric ligand; Autoantibodies; CADD; Gpcrs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Abdel-Magid F (2015) Allosteric modulators: an emerging concept in drug discovery. ACS Med Chem Lett 6:104–107 - PubMed - PMC
    1. Acharya A, Coop JE, Polli AD, Mackerell Jr (2011) Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des 7:10–22 - PubMed - PMC
    1. Balakrishnan A, Polli JE (2006) Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm 3:223–230 - PubMed - PMC
    1. Butkiewicz M et al (2019) Identification of novel allosteric modulators of metabotropic glutamate receptor subtype 5 acting at site distinct from 2-methyl-6-(phenylethynyl)-pyridine binding. ACS Chem Neurosci 10:3427–3436 - PubMed - PMC
    1. Cabral-Marques O et al (2018) GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat Commun 9:5224 - PubMed - PMC

Publication types

LinkOut - more resources